Glaukos Completes Enrollment in Phase 2 Trial for Demodex Blepharitis Treatment — Glaukos Corporation

Event summary

Glaukos has completed patient enrollment in its Phase 2 study of GLK-321, a treatment for Demodex blepharitis.
The trial randomized 275 patients across U.S. clinical sites to evaluate safety, tolerability, and efficacy of three dose levels.
GLK-321 uses Glaukos’ proprietary iLution platform, a cream-based drug-delivery system for dropless transdermal delivery.
Primary endpoint assesses the proportion of study eyes achieving elimination of collarettes after six weeks of treatment.

The big picture

Glaukos is advancing its pipeline beyond glaucoma with GLK-321, targeting a chronic eyelid disease with significant unmet needs. The iLution platform represents a strategic shift toward dropless therapies, aiming to improve compliance and reduce patient burden. Success in this trial could position Glaukos as a key player in ocular surface disease treatments.

What we're watching

Regulatory Pathway: How the Phase 2 results will shape GLK-321’s regulatory strategy and potential approval timeline.
Market Opportunity: Whether Glaukos can capitalize on the underpenetrated Demodex blepharitis market with differentiated therapies.
Platform Scalability: The pace at which Glaukos can expand its iLution platform into other ocular surface diseases.